Immunization of cancer {#s1}
======================

After successful accomplishment of a number of studies as \"proof-of-concept\" upon the cell-based vaccinations, the first \"proof-of-technology\" and more realistically \"proof-of-marketing\" was emerged as sipuleucel-T (also known as APC8015/Provenge™) by Dendreon Corp. (Seattle, WA, USA). Sipuleucel-T was approved by the United State Food and Drug Administration (FDA) in 2010 for the treatment of prostate cancer, which showed evidence of efficacy in lessening mortality risk among men with metastatic castration-resistant prostate cancer (MCRPC).^[@R1]-[@R3]^ As the first FDA approved autologous active cellular immunotherapy modality, Sipuleucel-T opened a new horizon for the cancer therapy and raised great hopes for the development of futuristic personalized immunotherapies and vaccines. For the proof-of-technology, Kantoff et al carried out a double-blind multicenter phase III trial, in which randomly assigned 512 patients were administered either sipuleucel-T (341 patients) or placebo (171 patients) intravenously every 2 weeks -- three infusions in total. In the group treated with sipuleucel-T, in comparison with the group treated with placebo, a significant reduction (22%) in the risk of death was observed with 36-month survival probability of 31.7%.^[@R2]^

As the first personalized medicine, sipuleucel-T has successfully been used for the treatment of asymptomatic/minimally symptomatic metastatic hormone-refractory prostate cancer (HRPC).^[@R3],[@R4]^ [Fig. 1](#F1){ref-type="fig"} schematically epitomizes the cell-based immunotherapy process using sipuleucel-T modality.
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As shown in [Fig. 1](#F1){ref-type="fig"}, the administration of sipuleucel-T needs three key steps of (*a*) isolation of the patient's antigen-presenting cells (APCs) such as dendritic cells (DCs) using a leukapheresis system, (*b*) incubation of the isolated cells with the fusion protein PA2024, which consists of the antigen prostatic acid phosphatase (PAP) and an immune signaling factor granulocyte-macrophage colony stimulating factor (GM-CSF), to reprogram the patient's APCs to present the required antigens, and (*c*) infusion of the activated blood product.

It should be noted that during invasion and metastasis in the most, if not all, of malignancies, traveling single cancer cells escape the \"anoikis\" phenomenon that is the main mechanism of death program for the homeless single cells unanchored the extracellular matrix. In 2004, Douma et al showed that the functional expression of TrkB protein favors cancer cells to run away the anoikis, in which the brain-derived neurotrophic factor (BDNF) stimulated TrkB protein can in turn activate the AKT/PKB proteins whose functions result in survival and proliferation of separated traveling cancer cells.^[@R6]^ Since then, several studies revealed that cancer cells recruit various bioelements to escape the anoikis.^[@R7]-[@R14]^ Taken all, some pivotal questions still remain unanswered, for example we must know how can really homeless single cancerous cells survive the anoikis and immunosurveillance? And, how effective would be the applied vaccination/immunotherapy against malignancies if some cancerous cells alter its characteristics to evade the immune system functions? We believe that the transitional alteration of differentiated cancer cells to the undedicated cancer stem cells, which can act as progenitor for the second colonization and relapse, is possible mechanism for the survival of single cancer cell invaders even though the detailed mechanism(s) by which invading tumor cells survive the anoikis process are yet to be fully understood.

So far, the chemotherapy of cancer has associated with some important shortcomings such as inadvertent side effects in the healthy cells, leading many scientists including our group to search for more cancer-specific treatment modalities such as multimodal nanomedicines and seamless theranostics.^[@R15]-[@R21]^ In addition, success of the currently used immunotherapy of cancer appears to be associated with some difficulties,^[@R22]-[@R25]^ so are the gene therapy modalities, while the gene delivery viral vectors^[@R26],[@R27]^ and nonviral vectors^[@R28]-[@R34]^ respectively induce intrinsic immunogenicity and genotoxicity.

In the case of cancer immunotherapy, two key strategies have currently been utilized for the tumor targeting, including (*a*) the antibody-directed targeting of toxic agents or cytolytic activity and (*b*) intensification of cellular immune responses against malignant cells. However, these approaches have resulted in limited successes, largely because of (*a*) the inadequate penetration and dissemination of antibodies (Abs) or Ab-conjugates in the tumor microenvironment (TME) as well as cancer cells and (*b*) the trivial activation of tumor-specific cytotoxic lymphocytes.^[@R35]^ In fact, in the solid tumors, the TME forms a permissive milieu with unique characteristics, inclusing (*a*) altered energetic pathways; for example glucose is hugely metabolized via glycolysis in favor of fueling of the lenient milieu of TME and remodeling of the extracellular matrix (ECM), (*b*) acidified extracellular fluid within the TME to reprogram the ECM and stromal cells in favor of the further invasion and metastasis, (*c*) transformed metabolism profile for some important biomolecules; for example, L-tryptophan is metabolized to produce kynurenine to favor the cancer cells to escape the anticancer immunosurveillance function of immune system and immunotherapies, (*d*) reprogramed stromal cells, (*e*) altered tumor interstitial fluid with high oncotic pressure, and (*f*) changed pattern of drug penetration into the core of solid tumor, in which passive diffusion no longer is the key player, and convection and migration phenomena of molecules/macromolecules impact dissemination of endogenous/exogenous compounds/particulates within TME.^[@R36],[@R37]^

Within the TME, even the transportation of the macromolecular nanosystems (NSs) through different paths (e.g., diffusion, migration and/or convection) would entirely differ from that of the normal tissues/cells. The tumor interstitial fluid pressure (IFP) is markedly high and hence the penetration of macromolecular anticancer agents into the deep core of solid tumor, where encompasses the cancer stem cells, appears to be intriguingly low in solid tumors. Further, the high microvascular density in the primary tumor is often associated with increased incidence of lymph node metastases as well as poor clinical outcome,^[@R38]^ and tumors with high IFP were reported to be dense in microvasculature in the periphery but possess large hypoxic fractions centrally. Hence, all these issues can limit the anticancer activity of immune system and immunotherapies.^[@R39]^

Up until now, a large number of clinical trials have been conducted for the cell-mediated vaccination of solid tumors, most of which were based on the use of tumor cells vaccines, modified lymphocytes and reprogramed APCs such as DCs to stimulate the immune responses through both CD4+ T helper cells and CD8+ cytotoxic T-lymphocytes (CTLs).^[@R40]-[@R44]^ Of these studies, implementation of fused DCs and tumor cells hybrids (the so-called dentritoma) seems to be a promising strategy even though some important inadequacies may limit its clinical usefulness as reported for DCs-based vaccination in the late stage melanoma.^[@R45]^ Combined immunotherapy and antivascular therapy has been proposed as an effective therapeutic modality in mice model bearing B16-F10 melanoma tumors to polarize the TME using a tumor cell-based vaccine (CAMEL peptide as a B16-F10 cell death-inducing agent). The combined therapy was found to induce profound inhibitory impacts as compared to monotherapies, resulting in lessened angiogenesis and increased tumor-infiltrating CD4+, CD8+ and NK cells with lowered suppressor T-lymphocytes (Tregs).^[@R46]^ [Table 1](#T1){ref-type="table"} represents some selected clinical trials on the cell-based vaccination of cancer.

###### Selected clinical trials for the cell-based vaccination of solid tumors

  --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ----------------------------- -------------------------------
  **Vaccination modality**                                                                                                                      **Trial description**                                                                                                                        **Cancer**                       **Phase, status**             **Clinical trial identifier**
  Autologous Ad HER2 dendritic cell vaccine                                                                                                     Ad/HER2/Neu dendritic cell cancer vaccine testing                                                                                            Breast                           I, recruiting                 NCT01730118
  Aldesleukin, filgrastim, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine   Gene-modified lymphocytes, high-dose aldesleukin, and vaccine therapy in treating patients with progressive or recurrent metastatic cancer   Various solid tumors             II, terminated with results   NCT00704938
  DEC-205/NY-ESO-1 fusion protein CDX-1401                                                                                                      Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors                                         Various solid tumors             I, active, not recruiting     NCT01522820
  CAP 1-6D and CMVpp65 peptide-pulsed, autologous dendritic cells                                                                               Vaccine therapy in treating patients with refractory stage IV cancer                                                                         Unspecified adult solid tumors   I, completed                  NCT00057915
  Dendritic cell vaccine loaded with autologous tumor                                                                                           Autologous OC-DC vaccine in ovarian cancer                                                                                                   Ovarian cancer                   0, recruiting                 NCT01132014
  Tumor Associated Peptide Antigens (TAPAz)-pulsed DC vaccine                                                                                   Treatment of patients with progressive and/or refractory solid malignancies                                                                  Various solid tumors             I/II, just initiated          NCT02224599
  Dendritic cell-gp100-MART-1 antigen vaccine                                                                                                   Vaccine therapy in treating patients with high-risk stage III or completely resected metastatic melanoma                                     Stage III/IV melanoma            II, completed                 NCT00019890
  --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ----------------------------- -------------------------------

Taken all, to tackle such hurdles, most of the strategies have been based on the enhancement of the immune system activity, for which the cell-based modalities against malignancies have been capitalized on the modulation of dendritic cells and/or lymphocytes.^[@R41],[@R43],[@R47]-[@R49]^ In these approaches, the foundation of immunotherapy is based on the reprograming of cellular elements of immune system towards modulation of both the innate and adaptive immunity of the patient.

Despite accomplishment of a large number of promising translational researches and clinical trials on the cell-based vaccination, still we do not have an ultimate immunization strategy against solid tumors. We believe that the status of TME in different solid tumors and penetration of macromolecules and immune system cells into such microenvironments must be fully understood. Further, we must address some pivotal issues to make sure upon the clinical benefits of the cell-based vaccination strategy. We need to answer some key questions. How effective would be the cell-based vaccination strategy if the core of solid tumors hosts some undedicated cancer stem cells (CSCs)? If such assumption is true, then what would be the best strategy for targeting CSCs? What would be the behavior of immune system components within TME with acidified tumor interstitial fluid and high oncotic pressure? Ideally, the use of panel of cancer molecular markers (CMMs) involved in TME^[@R50],[@R51]^ can be beneficial for the development of the cell-based immunotherapies and vaccination which will literally benefit both the antibody-directed and cell-mediated immunotherapy, and hence improve the survival rate. Thus, key CMMs of TME should be recognized. To this end, we need to comprehend the whole panel of molecular event in the TME as complex systems and design the cell-based immunization/vaccination in a holistic manner for each cancer patient exclusively.
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